Your browser is no longer supported. Please, upgrade your browser.
Settings
CBIO Catalyst Biosciences, Inc. daily Stock Chart
CBIO [NASD]
Catalyst Biosciences, Inc.
Index- P/E- EPS (ttm)-2.66 Insider Own0.20% Shs Outstand11.59M Perf Week7.90%
Market Cap112.42M Forward P/E- EPS next Y-3.54 Insider Trans-0.74% Shs Float11.13M Perf Month10.23%
Income-30.10M PEG- EPS next Q-1.08 Inst Own74.70% Short Float9.01% Perf Quarter4.75%
Sales0.01M P/S18737.17 EPS this Y64.00% Inst Trans-1.91% Short Ratio3.84 Perf Half Y3.74%
Book/sh10.04 P/B0.97 EPS next Y22.70% ROA-22.10% Target Price25.38 Perf Year-65.92%
Cash/sh10.36 P/C0.94 EPS next 5Y- ROE-22.70% 52W Range6.20 - 29.99 Perf YTD22.94%
Dividend- P/FCF- EPS past 5Y63.40% ROI- 52W High-67.66% Beta2.20
Dividend %- Quick Ratio25.80 Sales past 5Y- Gross Margin- 52W Low56.45% ATR0.54
Employees21 Current Ratio25.80 Sales Q/Q-100.00% Oper. Margin- RSI (14)64.71 Volatility4.00% 6.25%
OptionableYes Debt/Eq0.00 EPS Q/Q28.10% Profit Margin- Rel Volume0.43 Prev Close9.69
ShortableYes LT Debt/Eq0.00 EarningsMar 07 BMO Payout- Avg Volume261.00K Price9.70
Recom1.70 SMA2011.03% SMA5013.24% SMA200-8.31% Volume111,737 Change0.10%
Jan-04-19Initiated Oppenheimer Outperform $24
Feb-12-18Reiterated B. Riley FBR, Inc. Buy $19 → $49
Feb-09-18Reiterated Chardan Capital Markets Buy $37.50 → $75
Feb-09-18Reiterated Chardan Capital Markets Buy $10 → $75
Dec-08-17Initiated B. Riley FBR, Inc. Buy $19
Jun-12-17Initiated Chardan Capital Markets Buy $10
Jun-06-17Initiated Ladenburg Thalmann Buy $11
Jun-30-16Initiated Rodman & Renshaw Buy $3.50
Mar-08-19 09:48PM  Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-07-19 08:00AM  Catalyst Biosciences Reports Fourth Quarter and Full-Year 2018 Operating & Financial Results and Provides a Corporate Update GlobeNewswire
Mar-06-19 08:00AM  Catalyst Biosciences Announces Poster Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting GlobeNewswire
Feb-19-19 08:10AM  New Research: Key Drivers of Growth for Omega Healthcare Investors, Cinedigm, Cardiovascular, Allegiant Travel, Catalyst Biosciences, and ESCO Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-08-19 08:00AM  Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress GlobeNewswire
Feb-06-19 08:00AM  Catalyst Biosciences Announces Preclinical Proof-of-Concept Data of Gene Therapy Candidate CB 2679d-GT for the Treatment of Hemophilia B GlobeNewswire -6.79%
Feb-05-19 08:00AM  Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference GlobeNewswire
Jan-31-19 08:30AM  Catalyst Biosciences Announces Oral and Poster Presentations at the 12th Annual Congress of the European Association for Haemophilia and Allied Disorders GlobeNewswire
Jan-22-19 02:21PM  Is Catalyst Biosciences, Inc.s (NASDAQ:CBIO) Balance Sheet A Threat To Its Future? Simply Wall St.
Jan-09-19 08:36AM  Zacks.com featured expert Kevin Matras highlights: Net Lease, K12, Brookline Bancorp, Catalyst Biosciences and Knoll Zacks
Jan-08-19 07:20AM  These 5 Stocks Make Great Buys on New Analyst Coverage Zacks
Dec-18-18 12:00PM  Catalyst Biosciences Hosts Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs GlobeNewswire
Dec-10-18 08:00AM  Catalyst Biosciences to Host a Research & Development Day Focused on Factor VIIa and Factor IX Hemophilia Programs GlobeNewswire
Dec-01-18 12:00PM  Catalyst Biosciences Announces Updated Positive Interim Data from Its Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors GlobeNewswire
Nov-21-18 11:56AM  What Did Catalyst Biosciences Incs (NASDAQ:CBIO) CEO Take Home Last Year? Simply Wall St.
Nov-02-18 08:00AM  Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition GlobeNewswire +9.26%
Nov-01-18 08:00AM  Catalyst Biosciences Reports Third Quarter Operating & Financial Results and Provides a Corporate Update GlobeNewswire +11.57%
Oct-25-18 07:30AM  Factors of Influence in 2018, Key Indicators and Opportunity within StoneMor Partners, Catalyst Biosciences, Kennametal, Emergent Biosolutions, Kimball International, and Tailored Brands New Research Emphasizes Economic Growth GlobeNewswire
Oct-24-18 08:00AM  Catalyst Biosciences Receives A Notice of Allowance from The Japan Patent Office Covering Modified Factor X Polypeptides GlobeNewswire
Sep-25-18 08:00AM  Catalyst Biosciences to Present at Two Upcoming Healthcare Investor Conferences GlobeNewswire
Sep-18-18 11:15AM  How Does Catalyst Biosciences Inc (NASDAQ:CBIO)s Prospect Stack Up To Its Healthcare Peers? Simply Wall St.
Sep-05-18 08:30AM  Market Trends Toward New Normal in Shutterstock, CrossAmerica Partners LP, Allegiance Bancshares, Portola Pharmaceuticals, StoneMor Partners, and Catalyst Biosciences Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-04-18 08:00AM  Catalyst Biosciences Announces Publication of Marzeptacog Alfa (Activated) Phase 1 Data in The Journal of Thrombosis and Haemostasis GlobeNewswire
Aug-30-18 08:00AM  Catalyst Biosciences to Present at H.C. Wainwright & Co. 20th Annual Global Investment Conference GlobeNewswire
Aug-15-18 08:30AM  Report: Developing Opportunities within The Providence Service, NVE, StoneMor Partners, Midland States, Destination XL Group, and Catalyst Biosciences Future Expectations, Projections Moving into 2018 GlobeNewswire
08:00AM  Catalyst Biosciences Announces Updated Positive Interim Data at the 2018 Hemophilia Drug Development Summit GlobeNewswire
Aug-13-18 08:00AM  Catalyst Biosciences Announces Oral Presentation at the 2018 Hemophilia Drug Development Summit GlobeNewswire
Aug-02-18 08:00AM  Catalyst Biosciences Reports Second Quarter Operating & Financial Results and Provides Corporate Update GlobeNewswire +6.55%
Aug-01-18 06:58AM  Zacks.com featured highlights include: Hilton Grand, Fastenal, Catalyst Biosciences, OpGen and ConforMIS Zacks
04:04AM  Catalyst Biosciences (CBIO) Enters Oversold Territory Zacks
Jul-31-18 01:35PM  5 Top-Ranked Stocks to Benefit From Rising P/E Investing InvestorPlace
08:22AM  5 Top-Ranked Stocks to Benefit From Rising P/E Investing Zacks
Jul-23-18 12:06PM  After the Latest Plunge, Catalyst Stock Just Might Be Worth Buying InvestorPlace
Jul-18-18 10:41AM  Catalyst Biosciences Shares Volatile On Positive Late-Stage Hemophilia Trial Results Benzinga
07:18AM  Catalyst Biosciences shares surge 23% on positive results for one patient in late-stage hemophilia trial MarketWatch
07:00AM  Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors GlobeNewswire
Jul-12-18 08:00AM  Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis GlobeNewswire
Jul-10-18 08:00AM  Catalyst Biosciences Announces Appointment of Grant Blouse, Ph.D., as Vice President of Translational Research GlobeNewswire
Jun-25-18 08:30AM  Catalyst Biosciences Joins the Russell 2000® Index GlobeNewswire
Jun-19-18 10:25AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Biosciences, Inc. (CBIO) ACCESSWIRE +14.82%
08:36AM  Implied Volatility Surging for Catalyst Biosciences (CBIO) Stock Options Zacks
08:10AM  Todays Research Reports on Stocks to Watch: PTC Therapeutics and Catalyst Biosciences ACCESSWIRE
08:00AM  Catalyst Biosciences to Present at the JMP Securities 2018 Life Sciences Conference GlobeNewswire
Jun-18-18 03:13PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Catalyst Biosciences, Inc. - CBIO PR Newswire -63.92%
01:33PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Catalyst Biosciences, Inc. (CBIO) PR Newswire
06:30AM  Catalyst Biosciences Provides Update on CB 2679d/ISU304 Factor IX Clinical Program in Hemophilia B GlobeNewswire
May-23-18 08:30AM  New Research Coverage Highlights BlackRock Capital Investment, Tootsie Roll Industries, Catalyst Biosciences, Macerich, Quotient Technology, and PennyMac Mortgage Investment Trust Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-09-18 06:07PM  Catalyst Biosciences to Host Key Opinion Leader Meeting on Novel Treatments for Hemophilia B and Hemophilia with Inhibitors GlobeNewswire
May-03-18 08:00AM  Catalyst Biosciences Reports First Quarter Operating & Financial Results and Provides Corporate Update GlobeNewswire
Apr-23-18 08:00AM  Catalyst Biosciences Announces Presentation at the 2018 Association for Research in Vision and Ophthalmology Annual Meeting GlobeNewswire
Apr-12-18 08:00AM  Catalyst Biosciences Announces Korean Ministry of Food and Drug Safety Approves Addition of Sixth Cohort to the Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B GlobeNewswire
Mar-30-18 08:30AM  Analysis: Positioning to Benefit within Catalyst Biosciences, CorEnergy Infrastructure Trust, PennyMac Mortgage Investment Trust, Raven Industries, Acacia Communications, and Sandy Spring Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-26-18 08:00AM  Catalyst Biosciences Receives $1.5 Million In Two Milestone Payments for Neuronal Nicotinic Receptor (NNR) Asset GlobeNewswire
Mar-19-18 08:00AM  Catalyst Biosciences to Present at The Needham and Company 17th Annual Healthcare Conference GlobeNewswire
Mar-09-18 07:40AM  Zacks.com featured highlights include: Unisys, Catalyst, Liberty and New Mountain Zacks
Mar-07-18 08:00AM  Catalyst Biosciences to Present at The Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-05-18 04:01PM  Catalyst Biosciences Announces the Calling of Remaining Warrants and Conversion of Remaining Series A Preferred Shares Issued April 12, 2017 GlobeNewswire +11.73%
Mar-01-18 08:30AM  Catalyst Biosciences Reports Fourth Quarter and Full-Year 2017 Operating & Financial Results and Provides Corporate Update GlobeNewswire
Feb-26-18 08:00AM  Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d GlobeNewswire
Feb-15-18 11:43AM  Catalyst Biosciences Announces Closing of Public Offering of Common Stock GlobeNewswire
Feb-13-18 08:46AM  Catalyst Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire
Feb-12-18 04:33PM  Catalyst Biosciences Announces Proposed Public Offering of Common Stock GlobeNewswire +10.73%
07:50AM  Wired News Catalyst Biosciences Shares Positive Top-line Data from Phase-1/2 Study of Subcutaneous CB 2679d for Hemophilia B ACCESSWIRE
Feb-09-18 01:42PM  Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product Benzinga +17.85%
07:30AM  Catalyst Biosciences Announces Positive Top-Line Data from Phase 1/2 Study of Subcutaneous CB 2679d/ISU304 in Individuals with Hemophilia B GlobeNewswire
Jan-31-18 10:23AM  Catalyst Biosciences to Present Multi-Dose Subcutaneous Data for CB 2679d in Individuals with Hemophilia B in an Oral Presentation at the 11th Annual Congress of EAHAD GlobeNewswire +19.37%
Jan-29-18 07:50AM  Analysis: Positioning to Benefit within Catalyst Biosciences, Sandy Spring, Kadant, MTS, Social Reality, and Equity Commonwealth Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -7.31%
Jan-04-18 08:00AM  Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors GlobeNewswire
Dec-22-17 12:15PM  Catalyst Biosciences Announces Closing of Public Offering of Common Stock GlobeNewswire +7.64%
Dec-20-17 06:34PM  Catalyst Biosciences Inc (NASDAQ:CBIO): Is Healthcare Attractive Relative To NasdaqCM Peers? Simply Wall St. +29.62%
09:11AM  Catalyst Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-19-17 04:51PM  Catalyst Biosciences Announces Proposed Public Offering of Common Stock GlobeNewswire -5.77%
Dec-18-17 08:00AM  Catalyst Biosciences Announces Acceleration of Phase 1/2 Trial of CB 2679d/ISU304 in Individuals with Hemophilia B GlobeNewswire
Dec-15-17 08:10AM  Todays Research Reports on Trending Tickers: Catalyst Biosciences and Valeant Pharmaceuticals ACCESSWIRE +5.64%
Dec-14-17 08:30AM  Catalyst Biosciences Announces Appointment of Edward Williams to its Board of Directors GlobeNewswire +11.45%
Dec-11-17 08:00AM  Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference GlobeNewswire +10.21%
Dec-09-17 09:30AM  Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference GlobeNewswire
Nov-29-17 03:07PM  Was Catalyst Biosciences Incs (CBIO) EPS Decline A Part Of Broader Industry Downturn? Simply Wall St. +6.57%
Nov-28-17 08:30AM  Catalyst Biosciences Strengthens Clinical Hemophilia Programs with Additions to its Senior Leadership Team GlobeNewswire -5.89%
Nov-20-17 08:10AM  Todays Research Reports on Trending Tickers: Catalyst Biosciences and Corcept Therapeutics ACCESSWIRE
Nov-14-17 08:49AM  Catalyst Biosciences Inc (CBIO): Time For A Financial Health Check Simply Wall St. -5.41%
Nov-13-17 09:25AM  Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Capital Cube +6.40%
Nov-02-17 08:30AM  Catalyst Biosciences Reports Third Quarter 2017 Operating & Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-17 09:01AM  Catalyst Biosciences Announces Oral Presentation on Interim Phase 1/2 Data of Subcutaneous CB 2679d/ISU304 in Hemophilia B Patients at American Society for Hematology GlobeNewswire
Oct-31-17 08:31AM  LifeSci Advisors Announces 11th Board Appointment Through Board Placement Initiative GlobeNewswire
Oct-26-17 08:00AM  Catalyst Biosciences Announces the Appointment of Industry Veteran Andrea Hunt to its Board of Directors GlobeNewswire
Oct-24-17 08:00AM  Catalyst Biosciences and Mosaic Biosciences Enter into Strategic Collaboration to Develop Intravitreal Anti-Complement Factor 3 (C3) Products for the Treatment of Dry AMD and Other Retinal Diseases GlobeNewswire
Sep-26-17 08:00AM  Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B GlobeNewswire
Sep-25-17 08:01AM  Catalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical Trial GlobeNewswire +5.81%
Sep-22-17 08:01AM  Catalyst Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference GlobeNewswire +9.05%
Sep-11-17 08:01AM  Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program GlobeNewswire
Sep-07-17 08:00AM  Today's Research Reports on Trending Tickers: Athersys and Catalyst Biosciences ACCESSWIRE -6.61%
Sep-06-17 08:01AM  Catalyst Biosciences Announces Positive Factor IX Clinical Data GlobeNewswire +11.50%
Sep-05-17 08:23PM  ETFs with exposure to Catalyst Biosciences, Inc. : September 6, 2017 Capital Cube
Aug-24-17 11:01AM  Catalyst Biosciences, Inc. :CBIO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-03-17 08:00AM  Catalyst Biosciences Reports Second Quarter 2017 Financial Results and Provides Subcutaneous (SQ) Hemophilia Program Update GlobeNewswire
Jul-06-17 08:01AM  Financial Milestone Achieved in Catalysts Subcutaneous Factor IX Program GlobeNewswire
Jun-28-17 08:00AM  Catalyst Biosciences Factor IX Granted Orphan Drug Designation in Europe GlobeNewswire
Jun-26-17 08:01AM  Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model GlobeNewswire
Jun-14-17 08:01AM  Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial GlobeNewswire
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Levy HowardChief Medical OfficerNov 26Option Exercise4.631496907,709Nov 27 05:01 PM
Levy HowardChief Medical OfficerNov 16Option Exercise4.631738017,733Nov 16 05:56 PM
Levy HowardChief Medical OfficerNov 16Sale11.001731,9037,560Nov 16 05:56 PM
Levy HowardChief Medical OfficerMay 03Option Exercise4.637,56035,0037,560May 04 04:58 PM
USMAN NASSIMPresident & CEOApr 04Option Exercise4.638840788Apr 06 05:03 PM
Payne FletcherChief Financial OfficerMar 26Option Exercise4.635927359Mar 28 04:11 PM